In re Johnson & Johnson (Risperdal)
Nov 04, 2013OUTCOME: $21 million settlement for the Commowealth of Virginia
Johnson & Johson allegedly defrauded taxpayers by marketing the antipsychotic drugs Risperdal and Invega for uses not approved by the Food and Drug Administration. Johnson & Johnson and subsidiary Jans ... sen Pharmaceuticals, Inc., also promoted that Risperdal be prescribed to children, the elderly, and those with mental disabilities despite warnings of significant health risks and despite no FDA approval for use in these patient populations and paid kickbacks to nursing homes for switching their patients to Risperdal.
